View Filing Data

Earnings (Loss) Per Share

Stockholders' Equity

6. Stockholders' Equity

Stock-based Compensation Expense

Stock-based compensation expense recognized during the three and nine months ended September 30, 2019 and 2018 is included in our consolidated statements of operations as shown in the below table. Stock-based compensation expense includes both non-cash expense related to grants of stock-based awards as well as cash expense related to the employee discount applied to purchases of our common stock under our employee stock purchase plan. No stock-based compensation costs were capitalized during the three and nine months ended September 30, 2019 and 2018.

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2019		2018		2019		2018
Cost of revenue:
Software delivery, support and maintenance	$	395	$	498	$	1,522	$	1,538
Client services		765		1,031		3,021		3,537
Total cost of revenue		1,160		1,529		4,543		5,075
Selling, general and administrative expenses		5,643		6,208		20,799		17,672
Research and development		1,677		2,349		7,125		7,248
Total stock-based compensation expense	$	8,480	$	10,086	$	32,467	$	29,995

Allscripts Long-Term Incentive Plan

We measure stock-based compensation expense at the grant date based on the fair value of the award. We recognize the expense for service-based share awards over the requisite service period on a straight-line basis, net of estimated forfeitures. We recognize the expense for performance-based and market-based share awards over the vesting period under the accelerated attribution method, net of estimated forfeitures. In addition, we recognize stock-based compensation cost for awards with performance conditions if and when we conclude that it is probable that the performance conditions will be achieved.

The fair value of service-based and performance-based restricted stock units is measured at the underlying closing share price of our common stock on the date of grant. The fair value of market-based restricted stock units is measured using the Monte Carlo pricing model. No stock options were granted during the three and nine months ended September 30, 2019 and 2018.

We granted stock-based awards as follows:

	Three Months Ended September 30, 2019				Nine Months Ended September 30, 2019
			Weighted-Average				Weighted-Average
			Grant Date				Grant Date
(In thousands, except per share amounts)	Shares		Fair Value		Shares		Fair Value
Service-based restricted stock units		0	$	0.00		3,973	$	9.85
Market-based restricted stock units with a service condition		0	$	0.00		700	$	11.74
		0	$	0.00		4,673	$	10.14

During the nine months ended September 30, 2019 and the year ended December 31, 2018, 1.5 million and 1.6 million shares of common stock, respectively, were issued in connection with the exercise of options and the release of restrictions on stock awards.

Net Share-settlements

Upon vesting, restricted stock units are generally net share-settled to cover the required withholding tax and the remaining amount is converted into an equivalent number of shares of common stock. The majority of restricted stock units and awards that vested during the nine months ended September 30, 2019 and 2018 were net-share settled such that we withheld shares with fair value equivalent to the employees’ minimum statutory obligation for the applicable income and other employment taxes and remitted the cash to the appropriate taxing authorities. Total payments for the employees' minimum statutory tax obligations to the taxing authorities are reflected as a financing activity within the accompanying consolidated statements of cash flows. The total shares withheld for the nine months ended September 30, 2019 and 2018 were 658 thousand and 629 thousand, respectively, and were based on the value of the restricted stock units on their vesting date as determined by our closing stock price. These net-share settlements had the effect of share repurchases by us as they reduced the number of shares that would have otherwise been issued as a result of the vesting.

Stock Repurchases

On November 17, 2016, we announced that our Board of Directors approved a stock purchase program (the “2016 Program”) under which we may repurchase up to $200 million of our common stock through December 31, 2019. On August 2, 2018, we announced that our Board of Directors approved a new stock purchase program (the “2018 Program”) under which we may repurchase up to $250 million of our common stock through December 31, 2020, replacing the 2016 Program. We repurchased 3.5 million of our common stock under the 2018 Program for a total of $37.1 million during the three months ended September 30, 2019. We repurchased 9.6 million shares of our common stock under the 2018 Program for a total of $102.2 million during the nine months ended September 30, 2019. We did initiate share transactions to purchase an additional 0.9 million shares for $9.3 million under the 2018 Program for the three months ended September 30, 2019, but the transactions were not settled until October 2019. The shares settled in October 2019 were outstanding as of September 30, 2019, and therefore will be recorded as a financing transaction as “Repurchase of unsettled common stock” within the consolidated statements of cash flows and recorded as “Other assets” within the consolidated balance sheets. The approximate dollar value of shares that may yet be purchased under the 2018 Program is $111.1 million as of September 30, 2019, which does not include the share transactions settled in October 2019. We repurchased 7.7 million shares of our common stock under the 2016 Program for a total of $101.9 million during the nine months ended September 30, 2018, of which none were repurchased during the three months ended September 30, 2018. Any future stock repurchase transactions may be made through open market transactions, block trades, privately negotiated transactions (including accelerated share repurchase transactions) or other means, subject to market conditions. Any repurchase activity will depend on many factors such as our working capital needs, cash requirements for investments, debt repayment obligations, economic and market conditions at the time, including the price of our common stock, and other factors that we consider relevant. Our stock repurchase program may be accelerated, suspended, delayed or discontinued at any time.

Earnings (Loss) Per Share

9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

7. Earnings (Loss) Per Share

Basic earnings (loss) per share is computed by dividing net income (loss) by the weighted-average shares of common stock outstanding. For purposes of calculating diluted earnings (loss) per share, the denominator includes both the weighted-average shares of common stock outstanding and dilutive common stock equivalents. Dilutive common stock equivalents consist of stock options, restricted stock unit awards and warrants calculated under the treasury stock method.

The calculations of earnings (loss) per share are as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands, except per share amounts)	2019			2018			2019			2018
Basic earnings (loss) per Common Share:
(Loss) income from continuing operations, net of tax	$	(5,725	)	$	(12,141	)	$	(163,632	)	$	47,264
Net loss attributable to non-controlling interests		0			4			424			3,494
Net (loss) income from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(5,725	)	$	(12,137	)	$	(163,208	)	$	50,758
Loss from discontinued operations, net of tax	$	0		$	(11,705	)	$	0		$	(25,353	)
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations		0			(12,149	)		0			(36,446	)
Net loss from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders		0			(23,854	)		0			(61,799	)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(5,725	)	$	(35,991	)	$	(163,208	)	$	(11,041	)

Weighted-average common shares outstanding		166,391			174,638			167,610			176,942

Basic (loss) earnings from continuing operations per Common Share	$	(0.03	)	$	(0.07	)	$	(0.97	)	$	0.28
Basic loss from discontinued operations per Common Share		0.00			(0.13	)		0.00			(0.34	)
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share	$	(0.03	)	$	(0.20	)	$	(0.97	)	$	(0.06	)

Diluted earnings (loss) per Common Share:
(Loss) income from continuing operations, net of tax	$	(5,725	)	$	(12,141	)	$	(163,632	)	$	47,264
Net loss attributable to non-controlling interests		0			4			424			3,494
Net (loss) income from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(5,725	)	$	(12,137	)	$	(163,208	)	$	50,758
Loss from discontinued operations, net of tax	$	0		$	(11,705	)	$	0		$	(25,353	)
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations		0			(12,149	)		0			(36,446	)
Net loss from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders		0			(23,854	)		0			(61,799	)
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(5,725	)	$	(35,991	)	$	(163,208	)	$	(11,041	)

Weighted-average common shares outstanding		166,391			174,638			167,610			176,942
Plus: Dilutive effect of stock options, restricted stock unit awards and warrants		0			0			0			0
Weighted-average common shares outstanding assuming dilution		166,391			174,638			167,610			176,942

Diluted (loss) earnings from continuing operations per Common Share	$	(0.03	)	$	(0.07	)	$	(0.97	)	$	0.28
Diluted loss from discontinued operations per Common Share		0.00			(0.13	)		0.00			(0.34	)
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share	$	(0.03	)	$	(0.20	)	$	(0.97	)	$	(0.06	)

Due to the net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders for the three and nine months ended September 30, 2019 and 2018, we used basic weighted-average common shares outstanding in the calculation of diluted loss per share for those periods, since the inclusion of any stock equivalents would be anti-dilutive.

The following stock options, restricted stock unit awards and warrants are not included in the computation of diluted earnings (loss) per share as the effect of including such stock options, restricted stock unit awards and warrants in the computation would be anti-dilutive:

Three Months Ended

September 30,

Nine Months Ended

September 30,

(In thousands)

2019

2018

2019

2018

Shares subject to anti-dilutive stock options, restricted stock

unit awards and warrants excluded from calculation

27,969

24,191

27,350

24,688

Goodwill and Intangible Assets

9 Months Ended

Sep. 30, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

8. Goodwill and Intangible Assets

Goodwill and intangible assets consist of the following:

	September 30, 2019							December 31, 2018
	Gross							Gross
	Carrying		Accumulated			Intangible		Carrying		Accumulated			Intangible
(In thousands)	Amount		Amortization			Assets, Net		Amount		Amortization			Assets, Net
Intangibles subject to amortization:
Proprietary technology	$	546,078	$	(428,261	)	$	117,817	$	537,834	$	(401,093	)	$	136,741
Customer contracts and relationships		710,853		(482,720	)		228,133		704,808		(462,468	)		242,340
Total	$	1,256,931	$	(910,981	)	$	345,950	$	1,242,642	$	(863,561	)	$	379,081

Intangibles not subject to amortization:
Registered trademarks						$	52,000						$	52,000
Goodwill							1,387,088							1,373,744
Total						$	1,439,088						$	1,425,744

Changes in the carrying amounts of goodwill by reportable segment for the nine months ended September 30, 2019 were as follows:

(In thousands)	Provider			Veradigm		Total
Balance as of December 31, 2018	$	1,254,284		$	119,460	$	1,373,744
Additions		0			13,707		13,707
Foreign exchange translation		(363	)		0		(363	)
Balance as of September 30, 2019	$	1,253,921		$	133,167	$	1,387,088

There are $13.5 million in accumulated impairment losses associated with our goodwill as of September 30, 2019 and December 31, 2018. Additions to goodwill in 2019 resulted from the purchase of the Pinnacle and Diabetes Collaborative Registries and a prescription drug software company. The goodwill for both purchases is expected to be deductible for tax purposes.

Debt

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

Debt

9. Debt

Debt outstanding, excluding lease obligations, consists of the following:

	September 30, 2019						December 31, 2018
(In thousands)	Principal Balance		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount		Principal Balance		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount
1.25% Cash Convertible Senior Notes	$	345,000	$	11,236	$	333,764	$	345,000	$	22,112	$	322,888
Senior Secured Credit Facility		585,000		5,628		579,372		350,000		6,038		343,962
Other debt		302		0		302		748		0		748
Total debt	$	930,302	$	16,864	$	913,438	$	695,748	$	28,150	$	667,598
Less: Debt payable within one year		359,067		493		358,574		20,538		479		20,059
Total long-term debt, less current maturities	$	571,235	$	16,371	$	554,864	$	675,210	$	27,671	$	647,539

Interest expense consists of the following:

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2019		2018		2019		2018
Interest expense	$	6,741	$	9,352	$	19,404	$	25,436
Amortization of discounts and debt issuance costs		4,098		3,899		12,043		11,489
Total interest expense	$	10,839	$	13,251	$	31,447	$	36,925

Interest expense related to 1.25% Notes, included in the table above, consists of the following:

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2019		2018		2019		2018
Coupon interest at 1.25%	$	1,078	$	1,078	$	3,234	$	3,234
Amortization of discounts and debt issuance costs		3,685		3,509		10,876		10,358
Total interest expense related to the 1.25% Notes	$	4,763	$	4,587	$	14,110	$	13,592

Allscripts Senior Secured Credit Facility

On February 15, 2018, Allscripts and Healthcare LLC entered into a Second Amended and Restated Credit Agreement (the “Second Amended Credit Agreement”), with JPMorgan Chase Bank, N.A., as administrative agent. The Second Amended Credit Agreement provides for a $400 million senior secured term loan (the “Term Loan”) and a $900 million senior secured revolving facility (the “Revolving Facility”), each with a five-year term. The Term Loan is repayable in quarterly installments, which began on June 30, 2018. A total of up to $50 million of the Revolving Facility is available for the issuance of letters of credit, up to $10 million of the Revolving Facility is available for swingline loans, and up to $100 million of the Revolving Facility could be borrowed under certain foreign currencies.

As of September 30, 2019, $335.0 million under the Term Loan, $250.0 million under the Revolving Facility, and $1.0 million in letters of credit were outstanding under the Second Amended Credit Agreement.

As of September 30, 2019, the interest rate on the borrowings under the Second Amended Credit Agreement was LIBOR plus 1.50%, which totaled 3.54%. We were in compliance with all covenants under the Second Amended Credit Agreement as of September 30, 2019.

On August 7, 2019, we entered into a First Amendment to the Second Amended Credit Agreement in order to remain compliant with the covenants of our Second Amended Credit Agreement. The First Amendment provides the financial flexibility to settle the U.S. Department of Justice’s investigations as discussed in Note 13, “Contingencies” while maintaining our compliance with the covenants of our Second Amended Credit Agreement. None of the original terms of our Second Amended Credit Agreement relating to scheduled future principal payments, applicable interest rates and margins or borrowing capacity under our Revolving Facility were amended. In connection with this amendment, we incurred fees and other costs totaling $0.8 million, of which a majority was capitalized.

As of September 30, 2019, we had $649.0 million available, net of outstanding letters of credit, under our Revolving Facility. There can be no assurance that we will be able to draw on the full available balance of our Revolving Facility if the financial institutions that have extended such credit commitments become unwilling or unable to fund such borrowings.

1.25% Cash Convertible Senior Notes

As of September 30, 2019, the if-converted value of the 1.25% Notes did not exceed the 1.25% Notes’ principal amount.

The following table summarizes future debt payment obligations as of September 30, 2019:


(In thousands)	Total		Remainder of 2019		2020		2021		2022		2023		Thereafter
1.25% Cash Convertible Senior Notes ⁽¹⁾	$	345,000	$	0	$	345,000	$	0	$	0	$	0	$	0
Term Loan		335,000		5,000		27,500		30,000		37,500		235,000		0
Revolving Facility ⁽²⁾		250,000		0		0		0		0		250,000		0
Other debt		302		302		0		0		0		0		0
Total debt	$	930,302	$	5,302	$	372,500	$	30,000	$	37,500	$	485,000	$	0

⁽¹⁾ Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

⁽²⁾ Assumes no additional borrowings after September 30, 2019, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.

Income Taxes

9 Months Ended

Sep. 30, 2019

Income Tax Disclosure [Abstract]

Income Taxes

10. Income Taxes

We account for income taxes under FASB Accounting Standards Codification 740, “Income Taxes” (“ASC 740”). We calculate the quarterly tax provision consistent with the guidance provided by ASC 740-270, whereby we forecast the estimated annual effective tax rate and then apply that rate to the year-to-date pre-tax book (loss) income. The effective tax rate may be subject to fluctuations during the year as new information is obtained, which may affect the assumptions used to estimate the annual effective rate, including factors such as the valuation allowances against deferred tax assets, the recognition or de-recognition of tax benefits related to uncertain tax positions, or changes in or the interpretation of tax laws in jurisdictions where the Company conducts business. There is no tax benefit recognized on certain of the net operating losses incurred due to insufficient evidence supporting the Company’s ability to use these losses in the future. The effective tax rates were as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands)	2019			2018			2019			2018
(Loss) income from continuing operations before income taxes	$	(6,490	)	$	(13,778	)	$	(162,992	)	$	53,182
Income tax benefit (provision)	$	765		$	1,637		$	(640	)	$	(5,918	)
Effective tax rate		11.8	%		11.9	%		(0.4	%)		11.1	%

Our provision for income taxes differs from the tax computed at the U.S. federal statutory income tax rate primarily due to permanent differences, income attributable to foreign jurisdictions taxed at different rates, state taxes, tax credits and certain discrete items. Our effective tax rate for the three and nine months ended September 30, 2019, compared with the prior year comparable periods, differs primarily due to higher tax shortfalls associated with stock-based compensation reflected in the provision for the three and nine months ended September 30, 2019 and release of valuation allowance of $14.5 million recorded in the nine months ended September 30, 2018.

In evaluating our ability to recover our deferred tax assets within the jurisdictions from which they arise, we consider all available evidence, including scheduled reversals of deferred tax liabilities, tax-planning strategies, and results of recent operations. In evaluating the objective evidence that historical results provide, we consider three years of cumulative operating income (loss). During the three months ended September 30, 2019, we recorded immaterial impacts for valuation allowances.

Our unrecognized income tax benefits were $20.3 million and $19.8 million as of September 30, 2019 and December 31, 2018, respectively. If any portion of our unrecognized tax benefits is recognized, it could impact our effective tax rate. The tax reserves are reviewed periodically and adjusted considering changing facts and circumstances, such as progress of tax audits, lapse of applicable statutes of limitations and changes in tax law.

Derivative Financial Instruments

9 Months Ended

Sep. 30, 2019

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Derivative Financial Instruments

11. Derivative Financial Instruments

The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates:

September 30, 2019

Asset Derivatives

Liability Derivatives

(In thousands)

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives qualifying as cash flow hedges:

Foreign exchange contracts

Prepaid expenses and

other current assets

131

Accrued expenses

Derivatives not subject to hedge accounting:

1.25% Call Option

Other assets

2,842

N/A

1.25% Embedded cash conversion option

N/A

Other liabilities

3,619

Total derivatives

2,973

3,619

December 31, 2018

Asset Derivatives

Liability Derivatives

(In thousands)

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives qualifying as cash flow hedges:

Foreign exchange contracts

Prepaid expenses and

other current assets

262

Accrued expenses

Derivatives not subject to hedge accounting:

1.25% Call Option

Other assets

9,104

N/A

1.25% Embedded cash conversion option

N/A

Other liabilities

9,974

Total derivatives

9,366

9,974

N/A – We define “N/A” as disclosure not being applicable

Foreign Exchange Contracts

We have entered into non-deliverable forward foreign currency exchange contracts with reputable banking counterparties to hedge a portion of our forecasted future Indian Rupee-denominated (“INR”) expenses against foreign currency fluctuations between the United States dollar and the INR. These forward contracts cover a percentage of forecasted monthly INR expenses over time. As of September 30, 2019, there were 3 forward contracts outstanding that were staggered to mature monthly starting in October 2019 and ending in December 2019. In the future, we may enter into additional forward contracts to increase the amount of hedged monthly INR expenses or initiate hedges for monthly periods beyond December 2019. As of September 30, 2019, the notional amount for each of the outstanding forward contracts was 160 million INR, or the equivalent of $2.3 million, based on the exchange rate between the United States dollar and the INR in effect as of September 30, 2019. These amounts also approximate the forecasted future INR expenses we target to hedge in any one month in the future. As of September 30, 2019, we estimate that $0.1 million of net unrealized derivative gains included in AOCI will be reclassified into income within the next twelve months.

The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss:

	Amount of Gain (Loss) Recognized in OCI						Amount of Gain (Loss) Reclassified from AOCI into Income
(In thousands)	Three Months Ended September 30, 2019			Nine Months Ended September 30, 2019		Location of Gain (Loss) Reclassified from AOCI into Income	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Foreign exchange contracts	$	(257	)	$	83	Cost of Revenue	$	16	$	76
						Selling, general and administrative expenses		12		53
						Research and development	$	19	$	85

	Amount of Gain (Loss) Recognized in OCI							Amount of Gain (Loss) Reclassified from AOCI into Income
(In thousands)	Three Months Ended September 30, 2018			Nine Months Ended September 30, 2018			Location of Gain (Loss) Reclassified from AOCI into Income	Three Months Ended September 30, 2018			Nine Months Ended September 30, 2018
Foreign exchange contracts	$	(1,803	)	$	(2,010	)	Cost of Revenue	$	(74	)	$	227
							Selling, general and administrative expenses		(50	)		180
							Research and development	$	(77	)	$	278

1.25% Call Option

In June 2013, concurrent with the issuance of the 1.25% Notes, we entered into privately negotiated hedge transactions with certain of the initial purchasers of the 1.25% Notes (collectively, the “1.25% Call Option”). Assuming full performance by the counterparties, the 1.25% Call Option is intended to offset cash payments in excess of the principal amount due upon any conversion of the 1.25% Notes.

The 1.25% Call Option, which is indexed to our common stock, is a derivative asset that requires mark-to-market accounting treatment (due to the cash settlement features) until the 1.25% Call Option settles or expires. The 1.25% Call Option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy.

The 1.25% Call Option does not qualify for hedge accounting treatment. Therefore, the change in fair value of these instruments is recognized immediately in our consolidated statements of operations in Other income, net. Because the terms of the 1.25% Call Option are substantially similar to those of the 1.25% Notes embedded cash conversion option, discussed below, we expect the net effect of those two derivative instruments on our earnings to be minimal.

1.25% Notes Embedded Cash Conversion Option

The embedded cash conversion option within the 1.25% Notes is required to be separated from the 1.25% Notes and accounted for separately as a derivative liability, with changes in fair value reported in our consolidated statements of operations in Other income, net until the cash conversion option settles or expires. The initial fair value liability of the embedded cash conversion option was $82.8 million, which simultaneously reduced the carrying value of the 1.25% Notes (effectively an original issuance discount). The embedded cash conversion option is measured and reported at fair value on a recurring basis, within Level 3 of the fair value hierarchy.

The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations:

	Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands)	2019			2018			2019			2018
1.25% Call Option	$	(3,567	)	$	15,043		$	(6,262	)	$	(13,108	)
1.25% Embedded cash conversion option		3,746			(15,503	)		6,355			12,870
Net (loss) income included in other income, net	$	179		$	(460	)	$	93		$	(238	)

Other Comprehensive Income

9 Months Ended

Sep. 30, 2019

Other Comprehensive Income

12. Other Comprehensive Income

Accumulated Other Comprehensive Loss

Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest.

(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Gains on Foreign Exchange Contracts			Total
Balance as of December 31, 2018 ⁽¹⁾	$	(5,584	)	$	195		$	(5,389	)
Other comprehensive income (loss) before reclassifications		(35	)		61			26
Net (gains) losses reclassified from accumulated other comprehensive loss		0			(158	)		(158	)
Net other comprehensive loss		(35	)		(97	)		(132	)
Balance as of September 30, 2019 ⁽²⁾	$	(5,619	)	$	98		$	(5,521	)

⁽¹⁾	^{Net of taxes of $68 thousand for unrealized net gains on foreign exchange contract derivatives and $149 thousand arising from the revaluation of tax effects included in accumulated other comprehensive income.}

⁽²⁾	^{Net of taxes of $34 thousand for unrealized net losses on foreign exchange contract derivatives.}

(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Gains on Foreign Exchange Contracts			Total
Balance as of December 31, 2017 ⁽¹⁾	$	(2,676	)	$	691		$	(1,985	)
Other comprehensive income (loss) before reclassifications		(1,622	)		(1,487	)		(3,109	)
Net (gains) losses reclassified from accumulated other comprehensive loss		0			(358	)		(358	)
Net other comprehensive income		(1,622	)		(1,845	)		(3,467	)
Balance as of September 30, 2018⁽²⁾	$	(4,298	)	$	(1,154	)	$	(5,452	)

⁽¹⁾ Net of taxes of $445 thousand for unrealized net gains on foreign exchange contract derivatives.

⁽²⁾ Net of taxes of $405 thousand for unrealized net losses on foreign exchange contract derivatives.

Income Tax Effects Related to Components of Other Comprehensive Income (Loss)

The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”):

	Three Months Ended September 30,
	2019								2018
(In thousands)	Before-Tax Amount			Tax Effect		Net Amount			Before-Tax Amount			Tax Effect			Net Amount
Foreign currency translation adjustments	$	(574	)	$	0	$	(574	)	$	(60	)	$	0		$	(60	)
Foreign exchange contracts:
Net (losses) gains arising during the period		(257	)		67		(190	)		(1,803	)		468			(1,335	)
Net losses (gains) reclassified into income ⁽¹⁾		(48	)		13		(35	)		201			(52	)		149
Net change in unrealized (losses) gains on foreign exchange contracts		(305	)		80		(225	)		(1,602	)		416			(1,186	)
Net (loss) gain on cash flow hedges		(305	)		80		(225	)		(1,602	)		416			(1,186	)
Other comprehensive (loss) income	$	(879	)	$	80	$	(799	)	$	(1,662	)	$	416		$	(1,246	)

⁽¹⁾	^{Tax effects for the three months ended September 30, 2018 include $149 thousand arising from the revaluation of tax effects included in accumulated other comprehensive income at December 31, 2017.}

	Nine Months Ended September 30,
	2019									2018
(In thousands)	Before-Tax Amount			Tax Effect			Net Amount			Before-Tax Amount			Tax Effect		Net Amount
Foreign currency translation adjustments	$	(35	)	$	0		$	(35	)	$	(1,622	)	$	0	$	(1,622	)
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net (losses) gains arising during the period		83			(22	)		61			(2,010	)		522		(1,488	)
Net (gains) losses reclassified into income ⁽¹⁾		(214	)		56			(158	)		(685	)		328		(357	)
Net change in unrealized (losses) gains on foreign exchange contracts		(131	)		34			(97	)		(2,695	)		850		(1,845	)
Net (loss) gain on cash flow hedges		(131	)		34			(97	)		(2,695	)		850		(1,845	)
Other comprehensive (loss) income	$	(166	)	$	34		$	(132	)	$	(4,317	)	$	850	$	(3,467	)

⁽¹⁾	^{Tax effects for the nine months ended September 30, 2018 include $149 thousand arising from the revaluation of tax effects included in accumulated other comprehensive income at December 31, 2017.}

Contingencies

9 Months Ended

Sep. 30, 2019

Commitments And Contingencies Disclosure [Abstract]

Contingencies

13. Contingencies

In addition to commitments and obligations in the ordinary course of business, we are currently subject to various legal proceedings and claims that have not been fully adjudicated. We intend to vigorously defend ourselves, as appropriate, in these matters.

No less than quarterly, we review the status of each significant matter and assess our potential financial exposure. We accrue a liability for an estimated loss if the potential loss from any legal proceeding or claim is considered probable and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made.

The outcome of legal proceedings is inherently uncertain, and we may incur substantial defense costs and expenses defending any of these matters. In the opinion of our management, except as set forth below with respected to the expected resolution of the Practice Fusion investigations, the ultimate disposition of pending legal proceedings or claims will not have a material adverse effect on our consolidated financial position, liquidity or results of operations. However, if one or more of these legal proceedings were resolved against or settled by us in a reporting period for amounts in excess of our management’s expectations, our consolidated financial statements for that and subsequent reporting periods could be materially adversely affected. Additionally, the resolution of a legal proceeding against us could prevent us from offering our products and services to current or prospective clients or cause us to incur increased compliance costs, either of which could further adversely affect our operating results.

On May 1, 2012, Physicians Healthsource, Inc. filed a class action complaint in the U.S. District Court for the Northern District of Illinois against us. The complaint alleges that, on multiple occasions between July 2008 and December 2011, we or our agent sent advertisements by fax to the plaintiff and a class of similarly situated persons, without first receiving the recipients’ express permission or invitation in violation of the Telephone Consumer Protection Act, 47 U.S.C. § 227 (the “TCPA”). The plaintiff sought $500 for each alleged violation of the TCPA, treble damages if the Court finds the violations to be willful, knowing or intentional, and injunctive and other relief. Allscripts answered the complaint denying all material allegations and asserting a number of affirmative defenses, as well as counterclaims for breach of a license agreement. On March 31, 2016, plaintiff filed its motion for class certification. On May 31, 2016, we filed our opposition to plaintiff’s motion for class certification, and simultaneously moved for summary judgment on all of plaintiff’s claims. On June 2, 2017, an order was entered denying class certification and, accordingly, the case will not proceed on a class-wide basis.

The Enterprise Information Solutions business (the “EIS Business”) acquired from McKesson Corporation (“McKesson”) on October 2, 2017 is subject to a May 2017 civil investigative demand (“CID”) from the U.S. Attorney’s Office for the Eastern District of New York. The CID requests documents and information related to the certification McKesson obtained for Horizon Clinicals in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program. In August 2018, McKesson received an additional CID seeking similar information for Paragon. McKesson has agreed, with respect to the CIDs, to indemnify Allscripts for amounts paid or payable to the government (or any private relator) involving any products or services marketed, sold or licensed by the EIS Business as of or prior to the closing of the acquisition.

Practice Fusion, acquired by Allscripts on February 13, 2018, received in March 2017 a request for documents and information from the U.S. Attorney’s Office for the District of Vermont pursuant to a CID. Between April 2018 and June 2019, Practice Fusion received from the U.S. Department of Justice (the “DOJ”) seven additional requests for documents and information through four additional CIDs and three Health Insurance Portability and Accountability Act (“HIPAA”) subpoenas. The document and information requests received by Practice Fusion related to both the certification Practice Fusion obtained in connection with the U.S. Department of Health and Human Services’ Electronic Health Record Incentive Program and Practice Fusion’s compliance with the Anti-Kickback Statute (“AKS”) and HIPAA as it relates to certain business practices engaged in by Practice Fusion. In March 2019, Practice Fusion received a grand jury subpoena in connection with a criminal investigation related to Practice Fusion’s compliance with the AKS. On August 6, 2019, Practice Fusion reached an agreement in principle with the DOJ to resolve all of the DOJ’s outstanding civil and criminal investigations, including the investigation by the U.S. Attorney’s Office for the District of Vermont. The terms of this agreement in principle, which is subject to final negotiation of settlement documents with the government, contemplate that Practice Fusion will pay $145.0 million and enter into a deferred prosecution agreement and a civil settlement agreement. It is anticipated that the deferred prosecution agreement will resolve allegations that Practice Fusion, long before its acquisition by Allscripts and concerning conduct about which Allscripts was unaware at the time of the acquisition, violated the AKS through the manner by which a sponsored Clinical Decision Support arrangement was sold to an opioid manufacturer. The companion civil settlement agreement is expected to resolve other AKS allegations made by the DOJ against Practice Fusion as well as False Claims Act allegations pertaining to Meaningful Use payments the federal government made to users of Practice Fusion’s EHR system. Other non-financial terms and conditions remain subject to negotiation, and the terms described above may change following further negotiation. The agreement in principle and the final settlement materials are subject to approval of supervisory personnel within the DOJ. The proposed settlement amount is included in Other income (loss), net within the consolidated statements of operations and Accrued expenses within the consolidated balance sheets as of and for the nine months ended September 30, 2019.

Discontinued Operations

9 Months Ended

Sep. 30, 2019

Discontinued Operations And Disposal Groups [Abstract]

Discontinued Operations

14. Discontinued Operations

Netsmart

On December 31, 2018, we sold all of the Class A Common Units of Netsmart LLC, a Delaware limited liability company (“Netsmart”), held by the Company. Prior to the sale, Netsmart comprised a separate reportable segment, which due to its significance to our historical consolidated financial statements and results of operations, is reported as a discontinued operation due to the sale.

The following table summarizes Netsmart’s major income and expense line items as reported in the consolidated statements of operations for the three and nine months ended September 30, 2018:

	Three Months Ended			Nine Months Ended
(In thousands)	September 30, 2018			September 30, 2018
Major income and expense line items related to Netsmart:
Revenue:
Software delivery, support and maintenance	$	56,259		$	157,393
Client services		33,590			96,773
Total revenue		89,849			254,166
Cost of revenue:
Software delivery, support and maintenance		16,441			45,110
Client services		23,905			68,440
Amortization of software development and acquisition related assets		9,084			24,991
Total cost of revenue		49,430			138,541
Gross profit		40,419			115,625
Selling, general and administrative expenses		25,089			74,390
Research and development		6,715			17,753
Amortization of intangible and acquisition-related assets		6,391			17,580
Income from discontinued operations of Netsmart		2,224			5,902
Interest expense		(16,092	)		(43,918	)
Other gain (loss)		11			(6	)
Loss from discontinued operations of Netsmart before income taxes		(13,857	)		(38,022	)
Income tax benefit		2,152			8,938
Loss from discontinued operations, net of tax for Netsmart	$	(11,705	)	$	(29,084	)

Horizon Clinicals and Series2000 Revenue Cycle

Two of the product offerings (Horizon Clinicals and Series2000 Revenue Cycle) acquired with the business combination with the EIS Business were sunset after March 31, 2018. The decision to discontinue maintaining and supporting these solutions was made prior to our acquisition of the EIS Business and, therefore, are presented below as discontinued operations. Until the end of the first quarter of 2018, we were involved in ongoing maintenance and support for these solutions until customers have transitioned to other platforms. No disposal gains or losses were recognized during the 2018 fiscal year related to these discontinued operations. We had $0.9 million of accrued expenses associated with the Horizon Clinicals and Series2000 Revenue Cycle businesses on the consolidated balance sheets as of December 31, 2018.

The following table summarizes the major classes of line items constituting income (loss) of the discontinued operations with the sunset businesses of Horizon Clinicals and Series2000 Revenue Cycle, as reported in the consolidated statements of operations for the three and nine months ended September 30, 2018:

	Three Months Ended		Nine Months Ended
(In thousands)	September 30, 2018		September 30, 2018
Major classes of line items constituting pretax profit (loss) of discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle:
Revenue:
Software delivery, support and maintenance	$	0	$	9,441
Client services		0		404
Total revenue		0		9,845
Cost of revenue:
Software delivery, support and maintenance		0		2,322
Client services		0		830
Total cost of revenue		0		3,152
Gross profit		0		6,693
Research and development		0		1,651
(Loss) income from discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle before income taxes		0		5,042
Income tax benefit (provision)		0		(1,311	)
(Loss) income from discontinued operations, net of tax for Horizon Clinicals and Series2000 Revenue Cycle	$	0	$	3,731

Business Segments

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Business Segments

15. Business Segments

We primarily derive our revenues from sales of our proprietary software (either as a direct license sale or under a subscription delivery model), which also serves as the basis for our recurring service contracts for software support and maintenance and certain transaction-related services. In addition, we provide various other client services, including installation, and managed services such as outsourcing, private cloud hosting and revenue cycle management.

During the first quarter of 2019, we realigned our reporting structure as a result of the divestiture of our investment in Netsmart on December 31, 2018, the evolution of the healthcare IT industry and our increased focus on the payer and life sciences market. As a result, we changed the presentation of our reportable segments to Provider and Veradigm. The new Provider segment is comprised of our core integrated clinical software applications, financial management and patient engagement solutions targeted at clients across the entire continuum of care. The new Veradigm segment primarily focuses on the payer and life sciences market. These changes to our reportable segments had no impact on operating segments. The segment disclosures below for the three and nine months ended September 30, 2018, have been revised to conform to the current year presentation.

As of September 30, 2019, we had eight operating segments, which are aggregated into two reportable segments. The Provider reportable segment includes the Hospitals and Health Systems, Ambulatory, CarePort, FollowMyHealth^®, EPSi^TM, EIS-Classics and 2bPrecise strategic business units, each of which represents a separate operating segment. This reportable segment derives its revenue from the sale of integrated clinical software applications, financial management and patient engagement solutions, which primarily include EHR-related software, connectivity and coordinated care solutions, financial and practice management software, related installation, support and maintenance, outsourcing, private cloud hosting, revenue cycle management, training and electronic claims administration services. The Veradigm reportable segment is comprised of the Veradigm business unit, which represents a separate operating segment. This reportable segment provides data-driven clinical insights with actionable tools for clinical workflow, research, analytics and media. Its solutions, targeted at key healthcare stakeholders, help improve the quality, efficiency and value of healthcare delivery.

Our Chief Operating Decision Maker (“CODM”) uses segment revenues, gross profit and income from operations as measures of performance and to make decisions about the allocation of resources. In determining these performance measures, we do not include in revenue the amortization of acquisition-related deferred revenue adjustments, which reflect the fair value adjustments to deferred revenue acquired in a business combination. We also exclude the amortization of intangible assets, stock-based compensation expense, expenses not reflective of our core business and transaction-related costs, and non-cash asset impairment charges from the operating segment data provided to our CODM. Expenses not reflective of our core business relate to certain severance, product consolidation, legal, consulting and other charges. Accordingly, these amounts are not included in our reportable segment results and are included in an “Unallocated Amounts” category within our segment disclosure. The “Unallocated Amounts” category also includes (i) corporate general and administrative expenses (including marketing expenses) and certain research and development expenses related to common solutions and resources that benefit all of our business units, all of which are centrally managed, and (ii) revenue and the associated cost from the resale of certain ancillary products, primarily hardware. We do not track our assets by segment.

	Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands)	2019			2018			2019			2018
Revenue:
Provider	$	396,679		$	402,213		$	1,194,976		$	1,226,104
Veradigm		41,680			38,775			115,317			95,079
Unallocated Amounts		5,825			(8,558	)		10,400			(13,567	)
Total revenue	$	444,184		$	432,430		$	1,320,693		$	1,307,616

Gross profit:
Provider	$	168,047		$	175,393		$	508,180		$	545,223
Veradigm		25,655			27,669			75,203			66,112
Unallocated Amounts		(18,400	)		(25,110	)		(49,864	)		(74,951	)
Total gross profit	$	175,302		$	177,952		$	533,519		$	536,384

Income (loss) from operations:
Provider	$	96,895		$	101,130		$	301,294		$	308,071
Veradigm		8,975			12,850			29,525			26,163
Unallocated Amounts		(102,688	)		(113,794	)		(320,249	)		(400,843	)
Total income (loss) from operations	$	3,182		$	186		$	10,570		$	(66,609	)

Supplemental Disclosures

9 Months Ended

Sep. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Supplemental Disclosures

16. Supplemental Disclosures

Supplemental Consolidated Statements of Cash Flows Information

The majority of the restricted cash balance as of September 30, 2019 and 2018 represents the remaining balance of the escrow account established as part of the acquisition of Netsmart in 2016, to be used by Netsmart to facilitate the integration of Allscripts’ former Homecare^TMbusiness.

	September 30,
(In thousands)	2019		2018
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	129,349	$	90,738
Restricted cash		9,375		11,286
Total cash, cash equivalents and restricted cash	$	138,724	$	102,024

	Nine Months Ended September 30,
(In thousands)	2019		2018
Supplemental non-cash information:
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operation	$	0	$	36,446
Contribution of assets in exchange for equity interest	$	0	$	4,000
Issuance of treasury stock to commercial partner	$	701	$	1,121

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of Allscripts Healthcare Solutions, Inc. (“Allscripts”) and its wholly-owned subsidiaries and controlled affiliates. All significant intercompany balances and transactions have been eliminated. Each of the terms “we,” “us,” “our” or the “Company” as used herein refers collectively to Allscripts Healthcare Solutions, Inc. and its wholly-owned subsidiaries and controlled affiliates, unless otherwise stated.
Unaudited Interim Financial Information	Unaudited Interim Financial Information The unaudited interim consolidated financial statements as of September 30, 2019 and for the three and nine months ended September 30, 2019 and 2018 have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (the “SEC”) for interim financial reporting. These interim consolidated financial statements are unaudited and, in the opinion of our management, include all adjustments, consisting of normal recurring adjustments and accruals, necessary to present fairly the consolidated financial statements for the periods presented in accordance with generally accepted accounting principles in the United States of America (“GAAP”). The consolidated results of operations for the three and nine months ended September 30, 2019 are not necessarily indicative of the results to be expected for the full year ending December 31, 2019. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted in accordance with the SEC's rules and regulations for interim reporting. The Company believes that the disclosures made are adequate to make these unaudited interim consolidated financial statements not misleading. They should be read in conjunction with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2018 (our “Form 10-K”).
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in accordance with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the consolidated financial statements and the accompanying notes. Actual results could differ materially from these estimates.
Change in Presentation	Change in Presentation During the first quarter of 2019, we changed our reportable segments from Clinical and Financial Solutions, Population Health and Unallocated to Provider, Veradigm and Unallocated. The business units reported within the historical segments have been reallocated into the new segments. Refer to Note 15 “Business Segments” for further discussion on the impact of the change.
Recently Adopted Accounting Pronouncements	Significant Accounting Policies We adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update No. 2016-02, “Leases (Topic 842)” (“ASU 2016-02”) on January 1, 2019 using the cumulative-effect adjustment transition method. This method requires us to recognize an adoption impact as a cumulative-effect adjustment to the January 1, 2019 retained earnings balance. Prior period balances were not adjusted upon adoption of this standard. The standard requires that leased assets and corresponding lease liabilities be recognized within the consolidated balance sheets as right-of-use assets and operating or financing lease liabilities. Please refer to Note 3 “Leases” for further discussion on the impact of adoption. Recently Adopted Accounting Pronouncements In August 2017, the FASB issued Accounting Standards Update No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities” (“ASU 2017-12”), which provides new accounting guidance to simplify and improve the reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements. In addition to that main objective, the amendments in ASU 2017-12 make certain targeted improvements to simplify the application of the hedge accounting guidance in current GAAP. We adopted ASU 2017-12 on January 1, 2019, and the adoption did not have any effect on our consolidated financial statements. In June 2018, the FASB issued Accounting Standards Update No. 2018-07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” (“ASU 2018-07”), which expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in its own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction with selling goods or services to customers. We adopted this standard on January 1, 2019, and the adoption did not have any effect on our consolidated financial statements.
Accounting Pronouncements Not Yet Adopted	Accounting Pronouncements Not Yet Adopted In August 2018, the FASB issued Accounting Standards Update No. 2018-13, “Fair Value Measurement (Topic 820) – Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”), which eliminates, adds and modifies certain disclosure requirements for fair value measurements. Entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, but public companies will be required to disclose the range and weighted-average of significant unobservable inputs used to develop Level 3 fair value measurements. ASU 2018-13 will be effective for all entities for interim and annual periods beginning after December 15, 2019, with early adoption permitted. We are currently evaluating the disclosure impact of this accounting guidance. In June 2016, the FASB issued Accounting Standards Update No. 2016-13, Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments” (“ASU 2016-13”). The guidance in ASU 2016-13 replaces the incurred loss impairment methodology under current GAAP. The new impairment model requires immediate recognition of estimated credit losses expected to occur for most financial assets and certain other instruments. For available-for-sale debt securities with unrealized losses, the losses will be recognized as allowances rather than reductions in the amortized cost of the securities. ASU 2016-13 is effective for annual periods beginning after December 15, 2019, and interim periods within those annual periods. Early adoption is permitted for fiscal years beginning after December 15, 2018. We are currently in the process of evaluating this new guidance, which we expect to have an impact on our consolidated financial statements and results of operations. We do not believe that any other recently issued, but not yet effective accounting standards, if adopted, will have a material impact on our consolidated financial statements.
Revenue Recognition	Revenue Recognition We recognize revenue only when we satisfy an identified performance obligation (or bundle of obligations) by transferring control of a promised product or service to a customer. We consider a product or service to be transferred when a customer obtains control because a customer has sole possession of the right to use (or the right to direct the use of) the product or service for the remainder of its economic life or to consume the product or service in its own operations. We evaluate the transfer of control primarily from the customer’s perspective as this reduces the risk that revenue is recognized for activities that do not transfer control to the customer. The majority of our revenue is recognized over time because a customer continuously and simultaneously receives and consumes the benefits of our performance. The exceptions to this pattern are our sales of perpetual and term software licenses, and hardware, where we determined that a customer obtains control of the asset upon granting of access, delivery or shipment.

Revenue from Contracts with Customers (Tables)

9 Months Ended

Sep. 30, 2019

Revenue Recognized Related To Various Performance Obligations And Elected Accounting Expedients

The breakdown of revenue recognized related based on the origination of performance obligations and elected accounting expedients is presented in the table below:

(In thousands)	Three Months Ended March 31, 2019		Three Months Ended June 30, 2019		Three Months Ended September 30, 2019
Revenue related to deferred revenue balance at beginning of period	$	126,184	$	146,150	$	151,543
Revenue related to new performance obligations satisfied during the period		248,221		233,696		228,927
Revenue recognized under "right-to-invoice" expedient		55,923		62,245		61,814
Reimbursed travel expenses, shipping and other revenue		1,721		2,369		1,900
Total revenue	$	432,049	$	444,460	$	444,184

(In thousands)	Three Months Ended March 31, 2018		Three Months Ended June 30, 2018		Three Months Ended September 30, 2018
Revenue related to deferred revenue balance at beginning of period	$	181,398	$	196,163	$	153,151
Revenue related to new performance obligations satisfied during the period		200,232		180,001		225,641
Revenue recognized under "right-to-invoice" expedient		49,403		62,533		51,288
Reimbursed travel expenses, shipping and other revenue		2,689		2,767		2,350
Total revenue	$	433,722	$	441,464	$	432,430

Revenue by Segment [Member]

Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments

	Three Months Ended September 30, 2019
(In thousands)	Provider		Veradigm		Unallocated		Total
Software delivery, support and maintenance	$	241,516	$	37,494	$	5,363	$	284,373
Client services		155,163		4,186		462		159,811
Total revenue	$	396,679	$	41,680	$	5,825	$	444,184

	Three Months Ended September 30, 2018
(In thousands)	Provider		Veradigm		Unallocated			Total
Software delivery, support and maintenance	$	241,142	$	35,686	$	(2,690	)	$	274,138
Client services		161,071		3,089		(5,868	)		158,292
Total revenue	$	402,213	$	38,775	$	(8,558	)	$	432,430

	Nine Months Ended September 30, 2019
(In thousands)	Provider		Veradigm		Unallocated		Total
Software delivery, support and maintenance	$	726,310	$	108,987	$	9,611	$	844,908
Client services		468,666		6,330		789		475,785
Total revenue	$	1,194,976	$	115,317	$	10,400	$	1,320,693

	Nine Months Ended September 30, 2018
(In thousands)	Provider		Veradigm		Unallocated			Total
Software delivery, support and maintenance	$	752,650	$	89,908	$	(3,382	)	$	839,176
Client services		473,454		5,171		(10,185	)		468,440
Total revenue	$	1,226,104	$	95,079	$	(13,567	)	$	1,307,616

Recurring and Non-recurring Revenue [Member]

Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments

The below tables summarize revenue by type and nature of revenue stream as well as by our reportable segments:

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2019		2018		2019		2018
Revenue:
Recurring revenue	$	349,455	$	349,404	$	1,048,204	$	1,063,440
Non-recurring revenue		94,729		83,026		272,489		244,176
Total revenue	$	444,184	$	432,430	$	1,320,693	$	1,307,616

Leases (Tables)

9 Months Ended

Sep. 30, 2019

Lessee Disclosure [Abstract]

Summary of Total Costs Associated with Leased Assets

Total costs associated with leased assets are as follows:

(In thousands)	Three Months Ended September 30, 2019			Nine Months Ended September 30, 2019
Operating lease cost ⁽¹⁾	$	7,113		$	20,881
Less: Sublease income		(824	)		(2,404	)
Total operating lease costs	$	6,289		$	18,477
Finance lease costs:
Amortization of right-of-use assets ⁽²⁾	$	34		$	122
Interest on lease liability ⁽³⁾		2			6
Total finance lease costs	$	36		$	128

⁽¹⁾	Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statement of operations.

⁽²⁾	Amortization of finance right-of-use assets is recognized on a straight-line basis and is included in in Selling, general and administrative expenses within the consolidated statement of operations.

⁽³⁾	Interest on finance lease liabilities is recorded as Interest expense within the consolidated statement of operations.

Supplemental Information for Operating and Finance Leases

Supplemental information for operating and finance leases is as follows:

(In thousands)	Nine Months Ended September 30, 2019
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$	22,211
Operating cash flows from finance leases	$	6
Financing cash flows from finance leases	$	108
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	$	144,080
Finance leases	$	263

Summary of Balance Sheet Location and Balances for Operating and Finance Leases

The balance sheet location and balances for operating and finance leases are as follows:

(In thousands, except lease term and discount rate)	September 30, 2019
Operating leases:
Right-of-use assets - operating leases	$	103,537
Current operating lease liabilities	$	24,451
Long-term operating lease liabilities	$	100,230

Finance leases:
Fixed assets, gross	$	524
Accumulated depreciation		357
Fixed assets, net	$	167

Current finance lease liabilities ⁽¹⁾	$	127
Long-term finance lease liabilities ⁽²⁾	$	57

Weighted average remaining lease term (in years)
Operating leases		6
Finance leases		2

Weighted average discount rate
Operating leases		4.3	%
Finance leases		5.1	%

⁽¹⁾	Current finance lease liabilities are included in Accrued expenses within the consolidated balance sheets.

⁽²⁾	Long-term finance lease liabilities are included in Other liabilities within the consolidated balance sheets.

Summary of Future Maturities of Lease and Non-Lease Components

	September 30, 2019
(In thousands)	Operating Leases			Finance Leases
Remainder of 2019	$	7,824		$	58
2020		27,923			85
2021		23,131			40
2022		21,630			7
2023		19,324			0
Thereafter		42,396			0
Total lease liabilities		142,228			190
Less: Amount representing interest		(17,547	)		(6	)
Less: Short-term lease liabilities		(24,451	)		(127	)
Total long-term lease liabilities	$	100,230		$	57

Fair Value Measurements and Long-term Investments (Tables)

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table summarizes our financial assets and liabilities measured at fair value on a recurring basis as of the respective balance sheet dates:

	Balance Sheet	September 30, 2019								December 31, 2018
(In thousands)	Classifications	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Foreign exchange derivative assets	Prepaid expenses and other current assets	$	0	$	131	$	0	$	131	$	0	$	262	$	0	$	262
1.25% Call Option	Other assets		0		0		2,842		2,842		0		0		9,104		9,104
Total assets		$	0	$	131	$	2,842	$	2,973	$	0	$	262	$	9,104	$	9,366

Contingent consideration - current	Accrued expenses	$	0	$	0	$	22,541	$	22,541	$	0	$	0	$	10,528	$	10,528
Contingent consideration - long-term	Other liabilities		0		0		3,546		3,546		0		0		15,317		15,317
1.25% Embedded cash conversion option	Other liabilities		0		0		3,619		3,619		0		0		9,974		9,974
Total liabilities		$	0	$	0	$	29,706	$	29,706	$	0	$	0	$	35,819	$	35,819

Summary of Changes in Assets and Liabilities Measured at Fair Value on Recurring Basis

The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at September 30, 2019 are summarized as follows:

(In thousands)	Contingent Consideration			1.25% Notes Call Spread Overlay
Balance at December 31, 2018	$	25,845		$	(870	)
Additions		11,791			0
Payments		(11,500	)		0
Fair value adjustments		(49	)		93
Balance at September 30, 2019	$	26,087		$	(777	)

Summary of Long-term Equity Investments Included in Other Assets

The following table summarizes our long-term equity investments which are included in Other assets in the accompanying consolidated balance sheets:

	Number of Investees		Original		Carrying Value at
(In thousands, except for number of investees)	at September 30, 2019		Cost		September 30, 2019		December 31, 2018
Equity method investments ⁽¹⁾		5	$	7,407	$	11,207	$	10,667
Cost method and available-for-sale investments		9		43,874		34,158		25,923
Total long-term equity investments		14	$	51,281	$	45,365	$	36,590

⁽¹⁾	^{Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.}

Stockholders' Equity (Tables)

9 Months Ended

Sep. 30, 2019

Stock-Based Compensation Expense

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2019		2018		2019		2018
Cost of revenue:
Software delivery, support and maintenance	$	395	$	498	$	1,522	$	1,538
Client services		765		1,031		3,021		3,537
Total cost of revenue		1,160		1,529		4,543		5,075
Selling, general and administrative expenses		5,643		6,208		20,799		17,672
Research and development		1,677		2,349		7,125		7,248
Total stock-based compensation expense	$	8,480	$	10,086	$	32,467	$	29,995

Stock-Based Awards Granted

We granted stock-based awards as follows:

	Three Months Ended September 30, 2019				Nine Months Ended September 30, 2019
			Weighted-Average				Weighted-Average
			Grant Date				Grant Date
(In thousands, except per share amounts)	Shares		Fair Value		Shares		Fair Value
Service-based restricted stock units		0	$	0.00		3,973	$	9.85
Market-based restricted stock units with a service condition		0	$	0.00		700	$	11.74
		0	$	0.00		4,673	$	10.14

Earnings (Loss) Per Share (Tables)

9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Calculations of Earnings (Loss) Per Share

The calculations of earnings (loss) per share are as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands, except per share amounts)	2019			2018			2019			2018
Basic earnings (loss) per Common Share:
(Loss) income from continuing operations, net of tax	$	(5,725	)	$	(12,141	)	$	(163,632	)	$	47,264
Net loss attributable to non-controlling interests		0			4			424			3,494
Net (loss) income from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(5,725	)	$	(12,137	)	$	(163,208	)	$	50,758
Loss from discontinued operations, net of tax	$	0		$	(11,705	)	$	0		$	(25,353	)
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations		0			(12,149	)		0			(36,446	)
Net loss from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders		0			(23,854	)		0			(61,799	)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(5,725	)	$	(35,991	)	$	(163,208	)	$	(11,041	)

Weighted-average common shares outstanding		166,391			174,638			167,610			176,942

Basic (loss) earnings from continuing operations per Common Share	$	(0.03	)	$	(0.07	)	$	(0.97	)	$	0.28
Basic loss from discontinued operations per Common Share		0.00			(0.13	)		0.00			(0.34	)
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share	$	(0.03	)	$	(0.20	)	$	(0.97	)	$	(0.06	)

Diluted earnings (loss) per Common Share:
(Loss) income from continuing operations, net of tax	$	(5,725	)	$	(12,141	)	$	(163,632	)	$	47,264
Net loss attributable to non-controlling interests		0			4			424			3,494
Net (loss) income from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(5,725	)	$	(12,137	)	$	(163,208	)	$	50,758
Loss from discontinued operations, net of tax	$	0		$	(11,705	)	$	0		$	(25,353	)
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations		0			(12,149	)		0			(36,446	)
Net loss from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders		0			(23,854	)		0			(61,799	)
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders	$	(5,725	)	$	(35,991	)	$	(163,208	)	$	(11,041	)

Weighted-average common shares outstanding		166,391			174,638			167,610			176,942
Plus: Dilutive effect of stock options, restricted stock unit awards and warrants		0			0			0			0
Weighted-average common shares outstanding assuming dilution		166,391			174,638			167,610			176,942

Diluted (loss) earnings from continuing operations per Common Share	$	(0.03	)	$	(0.07	)	$	(0.97	)	$	0.28
Diluted loss from discontinued operations per Common Share		0.00			(0.13	)		0.00			(0.34	)
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders per Common Share	$	(0.03	)	$	(0.20	)	$	(0.97	)	$	(0.06	)

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share

Three Months Ended

September 30,

Nine Months Ended

September 30,

(In thousands)

2019

2018

2019

2018

Shares subject to anti-dilutive stock options, restricted stock

unit awards and warrants excluded from calculation

27,969

24,191

27,350

24,688

Goodwill and Intangible Assets (Tables)

9 Months Ended

Sep. 30, 2019

Goodwill And Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

Goodwill and intangible assets consist of the following:

	September 30, 2019							December 31, 2018
	Gross							Gross
	Carrying		Accumulated			Intangible		Carrying		Accumulated			Intangible
(In thousands)	Amount		Amortization			Assets, Net		Amount		Amortization			Assets, Net
Intangibles subject to amortization:
Proprietary technology	$	546,078	$	(428,261	)	$	117,817	$	537,834	$	(401,093	)	$	136,741
Customer contracts and relationships		710,853		(482,720	)		228,133		704,808		(462,468	)		242,340
Total	$	1,256,931	$	(910,981	)	$	345,950	$	1,242,642	$	(863,561	)	$	379,081

Intangibles not subject to amortization:
Registered trademarks						$	52,000						$	52,000
Goodwill							1,387,088							1,373,744
Total						$	1,439,088						$	1,425,744

Changes in Carrying Amount of Goodwill

Changes in the carrying amounts of goodwill by reportable segment for the nine months ended September 30, 2019 were as follows:

(In thousands)	Provider			Veradigm		Total
Balance as of December 31, 2018	$	1,254,284		$	119,460	$	1,373,744
Additions		0			13,707		13,707
Foreign exchange translation		(363	)		0		(363	)
Balance as of September 30, 2019	$	1,253,921		$	133,167	$	1,387,088

Debt (Tables)

9 Months Ended

Sep. 30, 2019

Debt Outstanding Excluding Lease Obligations

Debt outstanding, excluding lease obligations, consists of the following:

	September 30, 2019						December 31, 2018
(In thousands)	Principal Balance		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount		Principal Balance		Unamortized Discount and Debt Issuance Costs		Net Carrying Amount
1.25% Cash Convertible Senior Notes	$	345,000	$	11,236	$	333,764	$	345,000	$	22,112	$	322,888
Senior Secured Credit Facility		585,000		5,628		579,372		350,000		6,038		343,962
Other debt		302		0		302		748		0		748
Total debt	$	930,302	$	16,864	$	913,438	$	695,748	$	28,150	$	667,598
Less: Debt payable within one year		359,067		493		358,574		20,538		479		20,059
Total long-term debt, less current maturities	$	571,235	$	16,371	$	554,864	$	675,210	$	27,671	$	647,539

Interest Expense

Interest expense consists of the following:

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2019		2018		2019		2018
Interest expense	$	6,741	$	9,352	$	19,404	$	25,436
Amortization of discounts and debt issuance costs		4,098		3,899		12,043		11,489
Total interest expense	$	10,839	$	13,251	$	31,447	$	36,925

Summary of Future Debt Payment Obligations

The following table summarizes future debt payment obligations as of September 30, 2019:


(In thousands)	Total		Remainder of 2019		2020		2021		2022		2023		Thereafter
1.25% Cash Convertible Senior Notes ⁽¹⁾	$	345,000	$	0	$	345,000	$	0	$	0	$	0	$	0
Term Loan		335,000		5,000		27,500		30,000		37,500		235,000		0
Revolving Facility ⁽²⁾		250,000		0		0		0		0		250,000		0
Other debt		302		302		0		0		0		0		0
Total debt	$	930,302	$	5,302	$	372,500	$	30,000	$	37,500	$	485,000	$	0

⁽¹⁾ Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

⁽²⁾ Assumes no additional borrowings after September 30, 2019, payment of any required periodic installments of principal and that all drawn amounts are repaid upon maturity.

1.25% Notes [Member]

Interest Expense Related to 1.25% Notes

Interest expense related to 1.25% Notes, included in the table above, consists of the following:

	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2019		2018		2019		2018
Coupon interest at 1.25%	$	1,078	$	1,078	$	3,234	$	3,234
Amortization of discounts and debt issuance costs		3,685		3,509		10,876		10,358
Total interest expense related to the 1.25% Notes	$	4,763	$	4,587	$	14,110	$	13,592

Income Taxes (Tables)

9 Months Ended

Sep. 30, 2019

Income Tax Disclosure [Abstract]

Effective Tax Rates

	Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands)	2019			2018			2019			2018
(Loss) income from continuing operations before income taxes	$	(6,490	)	$	(13,778	)	$	(162,992	)	$	53,182
Income tax benefit (provision)	$	765		$	1,637		$	(640	)	$	(5,918	)
Effective tax rate		11.8	%		11.9	%		(0.4	%)		11.1	%

Derivative Financial Instruments (Tables)

9 Months Ended

Sep. 30, 2019

Derivative Instruments And Hedging Activities Disclosure [Abstract]

Fair Value and Balance Sheet Locations

The following tables provide information about the fair values of our derivative financial instruments as of the respective balance sheet dates:

September 30, 2019

Asset Derivatives

Liability Derivatives

(In thousands)

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives qualifying as cash flow hedges:

Foreign exchange contracts

Prepaid expenses and

other current assets

131

Accrued expenses

Derivatives not subject to hedge accounting:

1.25% Call Option

Other assets

2,842

N/A

1.25% Embedded cash conversion option

N/A

Other liabilities

3,619

Total derivatives

2,973

3,619

December 31, 2018

Asset Derivatives

Liability Derivatives

(In thousands)

Balance Sheet Location

Fair Value

Balance Sheet Location

Fair Value

Derivatives qualifying as cash flow hedges:

Foreign exchange contracts

Prepaid expenses and

other current assets

262

Accrued expenses

Derivatives not subject to hedge accounting:

1.25% Call Option

Other assets

9,104

N/A

1.25% Embedded cash conversion option

N/A

Other liabilities

9,974

Total derivatives

9,366

9,974

Derivatives Instruments Designated as Cash Flow Hedges

The following tables show the impact of derivative instruments designated as cash flow hedges on the consolidated statements of operations and the consolidated statements of comprehensive loss:

	Amount of Gain (Loss) Recognized in OCI						Amount of Gain (Loss) Reclassified from AOCI into Income
(In thousands)	Three Months Ended September 30, 2019			Nine Months Ended September 30, 2019		Location of Gain (Loss) Reclassified from AOCI into Income	Three Months Ended September 30, 2019		Nine Months Ended September 30, 2019
Foreign exchange contracts	$	(257	)	$	83	Cost of Revenue	$	16	$	76
						Selling, general and administrative expenses		12		53
						Research and development	$	19	$	85

	Amount of Gain (Loss) Recognized in OCI							Amount of Gain (Loss) Reclassified from AOCI into Income
(In thousands)	Three Months Ended September 30, 2018			Nine Months Ended September 30, 2018			Location of Gain (Loss) Reclassified from AOCI into Income	Three Months Ended September 30, 2018			Nine Months Ended September 30, 2018
Foreign exchange contracts	$	(1,803	)	$	(2,010	)	Cost of Revenue	$	(74	)	$	227
							Selling, general and administrative expenses		(50	)		180
							Research and development	$	(77	)	$	278

Net Impact of Changes in Fair Value of Call Option and Embedded Cash Conversion Option

The following table shows the net impact of the changes in fair values of the 1.25% Call Option and the 1.25% Notes’ embedded cash conversion option in the consolidated statements of operations:

	Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands)	2019			2018			2019			2018
1.25% Call Option	$	(3,567	)	$	15,043		$	(6,262	)	$	(13,108	)
1.25% Embedded cash conversion option		3,746			(15,503	)		6,355			12,870
Net (loss) income included in other income, net	$	179		$	(460	)	$	93		$	(238	)

Other Comprehensive Income (Tables)

9 Months Ended

Sep. 30, 2019

Components of Accumulated Other Comprehensive Loss

Changes in the balances of each component included in AOCI are presented in the tables below. All amounts are net of tax and exclude non-controlling interest.

(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Gains on Foreign Exchange Contracts			Total
Balance as of December 31, 2018 ⁽¹⁾	$	(5,584	)	$	195		$	(5,389	)
Other comprehensive income (loss) before reclassifications		(35	)		61			26
Net (gains) losses reclassified from accumulated other comprehensive loss		0			(158	)		(158	)
Net other comprehensive loss		(35	)		(97	)		(132	)
Balance as of September 30, 2019 ⁽²⁾	$	(5,619	)	$	98		$	(5,521	)

⁽¹⁾	^{Net of taxes of $68 thousand for unrealized net gains on foreign exchange contract derivatives and $149 thousand arising from the revaluation of tax effects included in accumulated other comprehensive income.}

⁽²⁾	^{Net of taxes of $34 thousand for unrealized net losses on foreign exchange contract derivatives.}

(In thousands)	Foreign Currency Translation Adjustments			Unrealized Net Gains on Foreign Exchange Contracts			Total
Balance as of December 31, 2017 ⁽¹⁾	$	(2,676	)	$	691		$	(1,985	)
Other comprehensive income (loss) before reclassifications		(1,622	)		(1,487	)		(3,109	)
Net (gains) losses reclassified from accumulated other comprehensive loss		0			(358	)		(358	)
Net other comprehensive income		(1,622	)		(1,845	)		(3,467	)
Balance as of September 30, 2018⁽²⁾	$	(4,298	)	$	(1,154	)	$	(5,452	)

⁽¹⁾ Net of taxes of $445 thousand for unrealized net gains on foreign exchange contract derivatives.

⁽²⁾ Net of taxes of $405 thousand for unrealized net losses on foreign exchange contract derivatives.

Income Tax Effects Related to Components of Other Comprehensive Income (Loss)

The following tables reflect the tax effects allocated to each component of other comprehensive income (loss) (“OCI”):

	Three Months Ended September 30,
	2019								2018
(In thousands)	Before-Tax Amount			Tax Effect		Net Amount			Before-Tax Amount			Tax Effect			Net Amount
Foreign currency translation adjustments	$	(574	)	$	0	$	(574	)	$	(60	)	$	0		$	(60	)
Foreign exchange contracts:
Net (losses) gains arising during the period		(257	)		67		(190	)		(1,803	)		468			(1,335	)
Net losses (gains) reclassified into income ⁽¹⁾		(48	)		13		(35	)		201			(52	)		149
Net change in unrealized (losses) gains on foreign exchange contracts		(305	)		80		(225	)		(1,602	)		416			(1,186	)
Net (loss) gain on cash flow hedges		(305	)		80		(225	)		(1,602	)		416			(1,186	)
Other comprehensive (loss) income	$	(879	)	$	80	$	(799	)	$	(1,662	)	$	416		$	(1,246	)

⁽¹⁾	^{Tax effects for the three months ended September 30, 2018 include $149 thousand arising from the revaluation of tax effects included in accumulated other comprehensive income at December 31, 2017.}

	Nine Months Ended September 30,
	2019									2018
(In thousands)	Before-Tax Amount			Tax Effect			Net Amount			Before-Tax Amount			Tax Effect		Net Amount
Foreign currency translation adjustments	$	(35	)	$	0		$	(35	)	$	(1,622	)	$	0	$	(1,622	)
Derivatives qualifying as cash flow hedges:
Foreign exchange contracts:
Net (losses) gains arising during the period		83			(22	)		61			(2,010	)		522		(1,488	)
Net (gains) losses reclassified into income ⁽¹⁾		(214	)		56			(158	)		(685	)		328		(357	)
Net change in unrealized (losses) gains on foreign exchange contracts		(131	)		34			(97	)		(2,695	)		850		(1,845	)
Net (loss) gain on cash flow hedges		(131	)		34			(97	)		(2,695	)		850		(1,845	)
Other comprehensive (loss) income	$	(166	)	$	34		$	(132	)	$	(4,317	)	$	850	$	(3,467	)

⁽¹⁾	^{Tax effects for the nine months ended September 30, 2018 include $149 thousand arising from the revaluation of tax effects included in accumulated other comprehensive income at December 31, 2017.}

Discontinued Operations (Tables)

9 Months Ended

Sep. 30, 2019

Netsmart [Member]

Summary of Discontinued Operations in Financial Statements

The following table summarizes Netsmart’s major income and expense line items as reported in the consolidated statements of operations for the three and nine months ended September 30, 2018:

	Three Months Ended			Nine Months Ended
(In thousands)	September 30, 2018			September 30, 2018
Major income and expense line items related to Netsmart:
Revenue:
Software delivery, support and maintenance	$	56,259		$	157,393
Client services		33,590			96,773
Total revenue		89,849			254,166
Cost of revenue:
Software delivery, support and maintenance		16,441			45,110
Client services		23,905			68,440
Amortization of software development and acquisition related assets		9,084			24,991
Total cost of revenue		49,430			138,541
Gross profit		40,419			115,625
Selling, general and administrative expenses		25,089			74,390
Research and development		6,715			17,753
Amortization of intangible and acquisition-related assets		6,391			17,580
Income from discontinued operations of Netsmart		2,224			5,902
Interest expense		(16,092	)		(43,918	)
Other gain (loss)		11			(6	)
Loss from discontinued operations of Netsmart before income taxes		(13,857	)		(38,022	)
Income tax benefit		2,152			8,938
Loss from discontinued operations, net of tax for Netsmart	$	(11,705	)	$	(29,084	)

Horizon Clinicals and Series2000 [Member]

Summary of Discontinued Operations in Financial Statements

	Three Months Ended		Nine Months Ended
(In thousands)	September 30, 2018		September 30, 2018
Major classes of line items constituting pretax profit (loss) of discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle:
Revenue:
Software delivery, support and maintenance	$	0	$	9,441
Client services		0		404
Total revenue		0		9,845
Cost of revenue:
Software delivery, support and maintenance		0		2,322
Client services		0		830
Total cost of revenue		0		3,152
Gross profit		0		6,693
Research and development		0		1,651
(Loss) income from discontinued operations for Horizon Clinicals and Series2000 Revenue Cycle before income taxes		0		5,042
Income tax benefit (provision)		0		(1,311	)
(Loss) income from discontinued operations, net of tax for Horizon Clinicals and Series2000 Revenue Cycle	$	0	$	3,731

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760

+ Details

Business Segments (Tables)

9 Months Ended

Sep. 30, 2019

Segment Reporting [Abstract]

Revenues and Income from Operations Related to Segment Within Reconciliation to Consolidated Amounts

	Three Months Ended September 30,						Nine Months Ended September 30,
(In thousands)	2019			2018			2019			2018
Revenue:
Provider	$	396,679		$	402,213		$	1,194,976		$	1,226,104
Veradigm		41,680			38,775			115,317			95,079
Unallocated Amounts		5,825			(8,558	)		10,400			(13,567	)
Total revenue	$	444,184		$	432,430		$	1,320,693		$	1,307,616

Gross profit:
Provider	$	168,047		$	175,393		$	508,180		$	545,223
Veradigm		25,655			27,669			75,203			66,112
Unallocated Amounts		(18,400	)		(25,110	)		(49,864	)		(74,951	)
Total gross profit	$	175,302		$	177,952		$	533,519		$	536,384

Income (loss) from operations:
Provider	$	96,895		$	101,130		$	301,294		$	308,071
Veradigm		8,975			12,850			29,525			26,163
Unallocated Amounts		(102,688	)		(113,794	)		(320,249	)		(400,843	)
Total income (loss) from operations	$	3,182		$	186		$	10,570		$	(66,609	)

Supplemental Disclosures (Tables)

9 Months Ended

Sep. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Supplemental Disclosures

	September 30,
(In thousands)	2019		2018
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	$	129,349	$	90,738
Restricted cash		9,375		11,286
Total cash, cash equivalents and restricted cash	$	138,724	$	102,024

	Nine Months Ended September 30,
(In thousands)	2019		2018
Supplemental non-cash information:
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operation	$	0	$	36,446
Contribution of assets in exchange for equity interest	$	0	$	4,000
Issuance of treasury stock to commercial partner	$	701	$	1,121

Revenue from Contracts with Customers - Additional Information (Detail) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($) Revenue_Stream	Sep. 30, 2018 USD ($)	Dec. 31, 2018 USD ($)
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Number of primary revenue streams \| Revenue_Stream			2
Total backlog	$ 3,900.0		$ 3,900.0
Total backlog, percentage, year one	38.00%		38.00%
Total backlog, percentage after year one	62.00%		62.00%
Selling, General and Administrative Expenses [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost Amortization	$ 7.5	$ 7.1	$ 22.5	$ 22.3
Prepaid Expenses and Other Current Assets [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost, Gross	20.9		20.9		$ 24.7
Other Assets [Member]
Revenue Initial Application Period Cumulative Effect Transition [Line Items]
Capitalized Contract Cost, Gross	$ 32.2		$ 32.2		$ 33.8

Revenue from Contract with Customer - Summary of Revenue Recognized Related to Various Performance Obligations and Elected accounting Expedients (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Revenue From Contract With Customer [Abstract]
Revenue related to deferred revenue balance at beginning of period	$ 151,543	$ 146,150	$ 126,184	$ 153,151	$ 196,163	$ 181,398
Revenue related to new performance obligations satisfied during the period	228,927	233,696	248,221	225,641	180,001	200,232
Revenue recognized under "right-to-invoice" expedient	61,814	62,245	55,923	51,288	62,533	49,403
Reimbursed travel expenses, shipping and other revenue	1,900	2,369	1,721	2,350	2,767	2,689
Total revenue	$ 444,184	$ 444,460	$ 432,049	$ 432,430	$ 441,464	$ 433,722	$ 1,320,693	$ 1,307,616

Revenue from Contracts with Customers - Summary of Revenue by Type and Nature of Revenue Stream by Reportable Segments (Detail) - USD ($) $ in Thousands	3 Months Ended						9 Months Ended
	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018
Disaggregation Of Revenue [Line Items]
Recurring revenue	$ 349,455			$ 349,404			$ 1,048,204	$ 1,063,440
Non-recurring revenue	94,729			83,026			272,489	244,176
Total revenue	444,184	$ 444,460	$ 432,049	432,430	$ 441,464	$ 433,722	1,320,693	1,307,616
Unallocated [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	5,825			(8,558)			10,400	(13,567)
Provider [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	396,679			402,213			1,194,976	1,226,104
Veradigm [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	41,680			38,775			115,317	95,079
Software delivery, Support and Maintenance [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	284,373			274,138			844,908	839,176
Software delivery, Support and Maintenance [Member] \| Unallocated [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	5,363			(2,690)			9,611	(3,382)
Software delivery, Support and Maintenance [Member] \| Provider [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	241,516			241,142			726,310	752,650
Software delivery, Support and Maintenance [Member] \| Veradigm [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	37,494			35,686			108,987	89,908
Client services [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	159,811			158,292			475,785	468,440
Client services [Member] \| Unallocated [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	462			(5,868)			789	(10,185)
Client services [Member] \| Provider [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	155,163			161,071			468,666	473,454
Client services [Member] \| Veradigm [Member] \| Operating Segments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 4,186			$ 3,089			$ 6,330	$ 5,171

Leases - Additional Information (Detail)	9 Months Ended
Leases - Additional Information (Detail)	Sep. 30, 2019
Minimum [Member]
Lessee Lease Description [Line Items]
Operating leases, remaining lease terms	1 year
Finance leases, remaining lease terms	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Operating leases, remaining lease terms	9 years
Finance leases, remaining lease terms	9 years
Operating leases, options to extend leases term	5 years
Finance leases, options to extend leases term	5 years
Operating leases, options to terminate leases term	1 year
Finance leases, options to terminate leases term	1 year

Leases - Summary of Total Costs Associated with Leased Assets (Detail) - USD ($)
$ in Thousands

3 Months Ended

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Operating lease cost

^[1]

$ 7,113

$ 20,881

Less: Sublease income

(824)

(2,404)

Total operating lease costs

6,289

18,477

Finance lease costs:

Amortization of right-of-use assets

^[2]

122

Interest on lease liability

^[3]

Total finance lease costs

$ 36

$ 128

[1]	Operating lease costs are recognized on a straight-line basis and are included in Selling, general and administrative expenses within the consolidated statement of operations.
[2]	Amortization of finance right-of-use assets is recognized on a straight-line basis and is included in in Selling, general and administrative expenses within the consolidated statement of operations.
[3]	Interest on finance lease liabilities is recorded as Interest expense within the consolidated statement of operations.

Leases - Supplemental Information for Operating and Finance Leases (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases	$ 22,211
Operating cash flows from finance leases	6
Financing cash flows from finance leases	108
Right-of-use assets obtained in exchange for lease obligations:
Operating leases	144,080
Finance leases	$ 263

Leases - Summary of Balance Sheet Location and Balances for Operating and Finance Leases (Detail) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Operating leases:

Right-of-use assets - operating leases

$ 103,537

$ 0

Current operating lease liabilities

24,451

Long-term operating lease liabilities

100,230

Finance leases:

Fixed assets, net

96,813

$ 121,913

Current finance lease liabilities

^[1]

$ 127

Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]

us-gaap:AccruedLiabilitiesCurrent

Long-term finance lease liabilities

^[2]

$ 57

Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]

us-gaap:OtherLiabilitiesNoncurrent

Weighted average remaining lease term (in years)

Operating leases

6 years

Finance leases

2 years

Weighted average discount rate

Operating leases

4.30%

Finance leases

5.10%

Finance Leases [Member]

Finance leases:

Fixed assets, gross

$ 524

Accumulated depreciation

357

Fixed assets, net

$ 167

[1]	Current finance lease liabilities are included in Accrued expenses within the consolidated balance sheets.
[2]	Long-term finance lease liabilities are included in Other liabilities within the consolidated balance sheets.

Leases - Summary of Future Maturities of Lease and Non-Lease Components (Detail) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

Operating Leases [Abstract]

Operating Leases, Remainder of 2019

$ 7,824

Operating Leases, 2020

27,923

Operating Leases, 2021

23,131

Operating Leases, 2022

21,630

Operating Leases, 2023

19,324

Operating Leases, Thereafter

42,396

Operating Leases, Total lease liabilities

142,228

Operating Leases, Less: Amount representing interest

(17,547)

Operating Leases, Less: Short-term lease liabilities

(24,451)

$ 0

Operating Leases, Total long-term lease liabilities

100,230

$ 0

Finance Leases [Abstract]

Finance Leases, Remainder of 2019

Finance Leases, Thereafter

Finance Leases, Total lease liabilities

190

Finance Leases, Less: Amount representing interest

(6)

Finance Leases, Less: Short-term lease liabilities

^[1]

(127)

Finance Leases, Total long-term lease liabilities

^[2]

$ 57

[1]	Current finance lease liabilities are included in Accrued expenses within the consolidated balance sheets.
[2]	Long-term finance lease liabilities are included in Other liabilities within the consolidated balance sheets.

Business Combinations - Additional Information (Detail) - USD ($)	Jul. 02, 2019	Mar. 01, 2019	Jun. 15, 2018
Business Acquisition [Line Items]
Acquisition of outstanding minority interest			$ 6,900,000
ACC Pinnacle and Diabetes Collaborative Registries [Member]
Business Acquisition [Line Items]
Total purchase price	$ 19,700,000
Purchase price initial payment	11,700,000
Contingent consideration, fair value at time of closing	5,000,000.0
ACC Pinnacle and Diabetes Collaborative Registries [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Potential milestone/earnout payments	$ 8,000,000.0
Pulse8, Inc. [Member]
Business Acquisition [Line Items]
Acquisition of outstanding minority interest		$ 53,800,000
Pulse8, Inc. [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Potential milestone/earnout payments		$ 10,000,000.0

Business Combinations - Other Acquisitions and Divestiture - Additional Information (Detail) - USD ($) $ in Thousands			3 Months Ended		9 Months Ended
	Jun. 15, 2018	Apr. 02, 2018	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Business Acquisition [Line Items]
Acquisition of outstanding minority interest in third party	$ 6,900
Pre-tax gain (loss) on sale of business			$ 0	$ 0	$ 0	$ 172,258
One Content Business [Member]
Business Acquisition [Line Items]
Date of divestiture		Apr. 02, 2018
Total consideration paid		$ 260,000
Pre-tax gain (loss) on sale of business						$ 177,900

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	$ 142,843	$ 142,455
Total assets	2,973	9,366
Total liabilities	29,706	35,819
Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	131	262
Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	22,541	10,528
Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	3,546	15,317
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	3,619	9,974
Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	0	0
Total liabilities	0	0
Level 1 [Member] \| Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 1 [Member] \| Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 1 [Member] \| Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 1 [Member] \| 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	131	262
Total liabilities	0	0
Level 2 [Member] \| Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	131	262
Level 2 [Member] \| Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	0	0
Level 2 [Member] \| Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 2 [Member] \| 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	0	0
Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Total assets	2,842	9,104
Total liabilities	29,706	35,819
Level 3 [Member] \| Foreign exchange derivative assets [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Prepaid expenses and other current assets	0	0
Level 3 [Member] \| Contingent Consideration Current [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Accrued expenses	22,541	10,528
Level 3 [Member] \| Contingent Consideration Long Term [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	3,546	15,317
Level 3 [Member] \| 1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other liabilities	3,619	9,974
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	2,842	9,104
1.25% Call Option [Member] \| Level 1 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
1.25% Call Option [Member] \| Level 2 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	0	0
1.25% Call Option [Member] \| Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Other assets	$ 2,842	$ 9,104

Summary of Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Parenthetical) (Detail)	Sep. 30, 2019
1.25% Notes Embedded Cash Conversion Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Interest rate	1.25%
1.25% Call Option [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Interest rate	1.25%

Summary of Changes in Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Balance at December 31, 2018	$ 25,845
Additions	11,791
Payments	(11,500)
Fair value adjustments	(49)
Balance at September 30, 2019	26,087
1.25% Notes Call Spread Overlay [Member]
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Roll Forward]
Balance at December 31, 2018	(870)
Additions	0
Payments	0
Fair value adjustments	93
Balance at September 30, 2019	$ (777)

Summary of Long-term Equity Investments Included in Other Assets (Detail)
$ in Thousands

9 Months Ended

Sep. 30, 2019

USD ($)

Investment

Dec. 31, 2018

USD ($)

Fair Value Disclosures [Abstract]

Equity method investments, Number of Investees | Investment

^[1]

Cost method and available-for-sale investments, Number of Investees | Investment

Total long-term equity investments, Number of Investees | Investment

Equity method investments, Original Cost

^[1]

$ 7,407

Cost method and available-for-sale investments, Original Cost

43,874

Total long-term equity investments, Original Cost

51,281

Equity method investments, Carrying Value

11,207

$ 10,667

Cost method and available-for-sale investments, Carrying Value

34,158

25,923

Total long-term equity investments, Carrying Value

$ 45,365

$ 36,590

[1]	^{Allscripts share of the earnings of our equity method investees is reported based on a one quarter lag.}

Fair Value Measurements and Long-term Investments - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Impairment recoveries			$ 1,000
Non-cash impairment charges of investments	$ 0	$ 0	$ (1,045)	$ 15,487
1.25% Cash Convertible Senior Notes [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Interest rate	1.25%		1.25%
Other Assets [Member]
Fair Value Balance Sheet Grouping Financial Statement Captions [Line Items]
Convertible note carrying value	$ 6,000		$ 6,000

Stockholders' Equity - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Aug. 02, 2018	Nov. 17, 2016
Class Of Stock [Line Items]
Capitalized stock-based compensation costs	$ 0	$ 0	$ 0	$ 0
Stock options granted	0	0	0	0
Share issued, exercise of options and release of stock awards			1,500,000		1,600,000
Shares settled for tax withholding			658,000	629,000
Common stock repurchased, amount			$ 102,160,000	$ 101,905,000
Repurchase of unsettled common stock			$ 9,301,000	$ 0
November 2016 Stock Repurchase Program [Member]
Class Of Stock [Line Items]
Stock repurchase program, authorized amount							$ 200,000,000
Common stock repurchased, shares		0		7,700,000
Common stock repurchased, amount				$ 101,900,000
August 2018 Stock Repurchase Program [Member]
Class Of Stock [Line Items]
Stock repurchase program, authorized amount						$ 250,000,000
Common stock repurchased, shares	3,500,000		9,600,000
Common stock repurchased, amount	$ 37,100,000		$ 102,200,000
Stock repurchase program, shares yet to be purchased	$ 111,100,000		$ 111,100,000
Repurchase of unsettled common stock, shares	900,000
Repurchase of unsettled common stock	$ 9,300,000
Transaction settlement date			2019-10

Stock-Based Compensation Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 8,480	$ 10,086	$ 32,467	$ 29,995
Cost of revenue [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	1,160	1,529	4,543	5,075
Cost of revenue [Member] \| Software delivery, Support and Maintenance [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	395	498	1,522	1,538
Cost of revenue [Member] \| Client services [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	765	1,031	3,021	3,537
Selling, General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	5,643	6,208	20,799	17,672
Research and development [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation expense	$ 1,677	$ 2,349	$ 7,125	$ 7,248

Stock-Based Awards Granted (Detail) - $ / shares shares in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	4,673
Weighted-Average Grant Date Fair Value, granted	$ 0.00	$ 10.14
Service-Based Restricted Stock Units [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	3,973
Weighted-Average Grant Date Fair Value, granted	$ 0.00	$ 9.85
Market-Based Restricted Stock Units with a Service Condition [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Shares, granted	0	700
Weighted-Average Grant Date Fair Value, granted	$ 0.00	$ 11.74

Calculations of Earnings (Loss) Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Basic earnings (loss) per Common Share:
(Loss) income from continuing operations, net of tax	$ (5,725)	$ (12,141)	$ (163,632)	$ 47,264
Net loss attributable to non-controlling interests	0	4	424	3,494
Net (loss) income from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	(5,725)	(12,137)	(163,208)	50,758
Less: Loss from discontinued operations	0	(11,705)	0	(25,353)
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations	0	(12,149)	0	(36,446)
Net loss from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	0	(23,854)	0	(61,799)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (5,725)	$ (35,991)	$ (163,208)	$ (11,041)
Weighted-average common shares outstanding	166,391	174,638	167,610	176,942
Basic (loss) earnings from continuing operations per Common Share	$ (0.03)	$ (0.07)	$ (0.97)	$ 0.28
Basic loss from discontinued operations per Common Share	0.00	(0.13)	0.00	(0.34)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$ (0.03)	$ (0.20)	$ (0.97)	$ (0.06)
Diluted earnings (loss) per Common Share:
(Loss) income from continuing operations, net of tax	$ (5,725)	$ (12,141)	$ (163,632)	$ 47,264
Net loss attributable to non-controlling interests	0	4	424	3,494
Net (loss) income from continuing operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	(5,725)	(12,137)	(163,208)	50,758
Loss from discontinued operations, net of tax	0	(11,705)	0	(25,353)
Accretion of redemption preference on redeemable convertible non-controlling interest - discontinued operations	0	(12,149)	0	(36,446)
Net loss from discontinued operations attributable to Allscripts Healthcare Solutions, Inc. stockholders	0	(23,854)	0	(61,799)
Net (loss) income attributable to Allscripts Healthcare Solutions, Inc. stockholders	$ (5,725)	$ (35,991)	$ (163,208)	$ (11,041)
Weighted-average common shares outstanding	166,391	174,638	167,610	176,942
Plus: Dilutive effect of stock options, restricted stock unit awards and warrants	0	0	0	0
Weighted-average common shares outstanding assuming dilution	166,391	174,638	167,610	176,942
Diluted (loss) earnings from continuing operations per Common Share	$ (0.03)	$ (0.07)	$ (0.97)	$ 0.28
Diluted loss from discontinued operations per Common Share	0.00	(0.13)	0.00	(0.34)
Net loss attributable to Allscripts Healthcare Solutions, Inc. stockholders per share	$ (0.03)	$ (0.20)	$ (0.97)	$ (0.06)

Anti-Dilutive Stock Options, Restricted Stock Unit Awards and Warrants Excluded from Computation of Diluted Earnings (Loss) Per Share (Detail) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Earnings Per Share [Abstract]
Shares subject to anti-dilutive stock options, restricted stock unit awards and warrants excluded from calculation	27,969	24,191	27,350	24,688

Goodwill and Intangible Assets (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Dec. 31, 2018
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,256,931	$ 1,242,642
Accumulated Amortization	(910,981)	(863,561)
Intangible Assets, Net	345,950	379,081
Registered trademarks	52,000	52,000
Goodwill	1,387,088	1,373,744
Total	1,439,088	1,425,744
Proprietary Technology [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	546,078	537,834
Accumulated Amortization	(428,261)	(401,093)
Intangible Assets, Net	117,817	136,741
Customer Contracts and Relationships [Member]
Schedule Of Goodwill And Intangible Assets [Line Items]
Gross Carrying Amount	710,853	704,808
Accumulated Amortization	(482,720)	(462,468)
Intangible Assets, Net	$ 228,133	$ 242,340

Changes in Carrying Amount of Goodwill (Detail) $ in Thousands	9 Months Ended
	Sep. 30, 2019 USD ($)
Goodwill [Line Items]
Goodwill	$ 1,373,744
Additions	13,707
Foreign exchange translation	(363)
Goodwill, net	1,387,088
Provider [Member]
Goodwill [Line Items]
Goodwill	1,254,284
Additions	0
Foreign exchange translation	(363)
Goodwill, net	1,253,921
Veradigm [Member]
Goodwill [Line Items]
Goodwill	119,460
Additions	13,707
Foreign exchange translation	0
Goodwill, net	$ 133,167

Goodwill and Intangible Assets - Additional Information (Detail) - USD ($) $ in Millions	Sep. 30, 2019	Dec. 31, 2018
Goodwill And Intangible Assets Disclosure [Abstract]
Accumulated impairment losses associated with goodwill	$ 13.5	$ 13.5

Debt Outstanding Excluding Lease Obligations (Detail) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

$ 930,302

$ 695,748

16,864

28,150

Principal Balance, Current

913,438

667,598

359,067

20,538

Unamortized Discount and Debt Issuance Costs, Current

493

479

Net Carrying Amount, Current

358,574

20,059

Principal Balance, Noncurrent

571,235

675,210

Unamortized Discount and Debt Issuance Costs, Noncurrent

16,371

27,671

Net Carrying Amount, Noncurrent

554,864

647,539

1.25% Cash Convertible Senior Notes [Member]

345,000

^[1]

345,000

11,236

22,112

Senior Secured Credit Facility [Member]

333,764

322,888

585,000

350,000

5,628

6,038

579,372

343,962

Other Debt [Member]

302

748

$ 302

$ 748

[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Interest Expense (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
Interest Expense (Detail) - USD ($) $ in Thousands	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Debt Instrument [Line Items]
Total interest expense	$ 10,839	$ 13,251	$ 31,447	$ 36,925
Convertible Senior Notes and Senior Secured Credit Facility [Member]
Debt Instrument [Line Items]
Interest expense	6,741	9,352	19,404	25,436
Amortization of discounts and debt issuance costs	4,098	3,899	12,043	11,489
Total interest expense	$ 10,839	$ 13,251	$ 31,447	$ 36,925

Interest Expense Related to 1.25% Notes (Detail) - 1.25% Notes [Member] - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Debt Instrument [Line Items]
Coupon interest at 1.25%	$ 1,078	$ 1,078	$ 3,234	$ 3,234
Amortization of discounts and debt issuance costs	3,685	3,509	10,876	10,358
Total interest expense related to the 1.25% Notes	$ 4,763	$ 4,587	$ 14,110	$ 13,592

Debt - Additional Information (Detail) - USD ($)

9 Months Ended

Aug. 07, 2019

Feb. 15, 2018

Sep. 30, 2019

Dec. 31, 2018

Senior Secured Term Loan [Member]

$ 930,302,000

$ 695,748,000

Senior Secured Revolving Facility [Member]

335,000,000

Credit facility, amount available

649,000,000.0

Senior Secured Credit Facility [Member]

1.25% Cash Convertible Senior Notes [Member]

585,000,000

350,000,000

Letter of Credit [Member]

$ 345,000,000

^[1]

$ 345,000,000

Interest rate

1.25%

Portion of facility available for issuance of letters of credit

$ 50,000,000

Line of Credit [Member]

Portion of facility available for issuance of swingline loans

10,000,000

Senior Secured Revolving Facility [Member]

Credit facility, maximum borrowing capacity

$ 900,000,000

Senior secured credit facilities term, years

5 years

Credit facility, maximum borrowing capacity, foreign currencies

$ 100,000,000

Senior Secured Term Loan [Member]

Credit facility, maximum borrowing capacity

$ 400,000,000

Senior secured credit facilities term, years

5 years

Line of credit facility, frequency of payments

The Term Loan is repayable in quarterly installments, which began on June 30, 2018.

Second Amended Credit Agreement [Member] | Senior Secured Term Loan [Member]

Second Amended Credit Agreement [Member] | Senior Secured Revolving Facility [Member]

$ 335,000,000.0

Second Amended Credit Agreement [Member] | Senior Secured Revolving Facility [Member] | United States dollars [Member]

$ 250,000,000.0

Debt instrument, interest rate, effective percentage

3.54%

Second Amended Credit Agreement [Member] | Senior Secured Revolving Facility [Member] | LIBOR Rate [Member]

Debt instrument, variable interest rate

1.50%

Second Amended Credit Agreement [Member] | Senior Secured Credit Facility [Member]

Letters of credit outstanding

$ 1,000,000.0

Fees and other costs, incurred

$ 800,000

[1]	Assumes no cash conversions of the 1.25% Notes prior to their maturity on July 1, 2020.

Summary of Future Debt Payment Obligations (Detail) - USD ($)
$ in Thousands

Sep. 30, 2019

Dec. 31, 2018

1.25% Cash Convertible Senior Notes [Member]

$ 930,302

$ 695,748

5,302

372,500

30,000

37,500

485,000

Senior Secured Term Loan [Member]

345,000

^[1]

345,000

Remainder of 2019

^[1]

2020

^[1]

345,000

^[1]

^[1]

^[1]

^[1]

335,000

5,000

27,500

30,000

37,500

235,000

Revolving Facility [Member]

302

$ 748

302